Efficacy of Phosphodiesterase-5 Inhibitor in Men With Premature Ejaculation: A New Systematic Review and Meta-analysis

Urology

Volumn 86, Issue 5, 2015, Pages 947-955

  Sun, Yi ^a   Luo, Deyi ^a   Yang, Lu ^a   Tang, Cai ^a   Yang, Tongxin ^a   Hu, Xiefeng ^a   Shen, Hong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AVANAFIL; DAPOXETINE; FLUOXETINE; PAROXETINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SILDENAFIL; TADALAFIL; VARDENAFIL;

ABNORMAL VISION; ARTICLE; ASTHENIA; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; EJACULATION; EJACULATION DISORDER; FATIGUE; HEADACHE; HEART PALPITATION; HUMAN; INTRAVAGINAL EJACULATION LATENCY TIME; LIBIDO DISORDER; LOSS OF APPETITE; MYALGIA; NAUSEA; NOSE OBSTRUCTION; PREMATURE EJACULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINITIS; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; CROSS-SECTIONAL STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; MALE; META ANALYSIS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; PHOSPHODIESTERASE 5 INHIBITORS; PREMATURE EJACULATION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84983504254     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2015.06.051     Document Type: Article

References (30)

1. Jannini, E.A., Lenzi, A., Ejaculatory disorders: epidemiology and current approaches to definition, classification and subtyping. World J Urol 23 (2005), 68–75.
2. Althof, S., Rosen, R., Symonds, T., et al. Development and validation of a new questionnaire to assess sexual satisfaction, control, and distress associated with premature ejaculation. J Sex Med 3 (2006), 465–475.
3. Symonds, T., Roblin, D., Hart, K., et al. How does premature ejaculation impact a man s life?. J Sex Marital Ther 29 (2003), 361–370.
4. Sotomayor, M., The burden of premature ejaculation: the patient's perspective. J Sex Med 2 (2005), 110–114.
5. Godpodinoff, M.L., Premature ejaculation: clinical subgroups and etiology. J Sex Marital Ther 15 (1989), 130–134.
6. McMahon, C.G., Althof, S., Waldinger, M.D., et al. An evidence-based definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation. BJU Int 102 (2008), 338–350.
7. Waldinger, M.D., Lifelong premature ejaculation: from authority-based to evidence-based medicine. BJU Int 95 (2005), 201–207.
8. Waldinger, M.D., Zwinderman, A.H., Schweitzer, D.H., et al. Relevance of methodological design for the interpretation of efficacy of drug treatment with premature ejaculation: a systematic review and meta-analysis-analysis. Int J Impot Res 16 (2004), 369–381.
9. Balon, R., Antidepressants in the treatment with premature ejaculation. J Sex Marital Ther 22 (1996), 85–96.
10. Hatzimouratidis, K., Amar, E., Eardley, I., et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 57 (2010), 804–814.
11. Abdel-Hamid, I.A., Phosphodiesterase 5 inhibitors in rapid ejaculation: potential use and possible mechanisms of action. Drugs 64 (2004), 13–26.
12. Asimakopoulos, A.D., Miano, R., Finazzi Agrò E., et al. Does current scientific and clinical evidence support the use of phosphodiesterase type 5 inhibitors for the treatment with premature ejaculation? A systematic review and meta-analysis analysis. J Sex Med 9 (2012), 2404–2416.
13. Gökçe, A., Halis, F., Demirtas, A., et al. The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study. BJU Int 107 (2011), 1274–1277.
14. Aversa, A., Pili, M., Francomano, D., et al. Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation. Int J Impot Res 21 (2009), 221–227.
15. Mathers, M.J., Klotz, T., Roth, S., et al. Safety and efficacy of vardenafil versus sertraline in the treatment with premature ejaculation: a randomised, prospective and crossover study. Andrologia 41 (2009), 169–175.
16. Mattos, R.M., Marmo Lucon, A., Srougi, M., Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urol Int 80 (2008), 162–165.
17. Higgins, J.P., Green, S., Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.4 (updated March 2011). 2011, The Cochrane Collaboration Available at: www.cochrane-handbook.org Accessed February 27, 2012.
18. Moher, D., Liberati, A., Tetzlaff, J., et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339 (2009), 336–341.
19. Polat, E.C., Ozbek, E., Otunctemur, A., et al. Combination therapy with selective serotonin reuptake inhibitors and phosphodiesterase-5 inhibitors in the treatment of premature ejaculation. Andrologia 47 (2015), 487–492.
20. Lee, W.K., Lee, S.H., Cho, S.T., et al. Comparison between on-demand dosing of dapoxetine alone and dapoxetie plus mirodenafil in patients with lifelong premature ejaculation: prospective, randomized, double-blind, placebo-controlled, multicenter study. J Sex Med 10 (2013), 2832–2841.
21. Hosseini, M.M., Yarmohammadi, H., Effect of fluoxetine alone and in combination with sildenafil in patients with premature ejaculation. Urol Int 79 (2007), 28–32.
22. Wang, W.F., Wang, Y., Minhas, S., et al. Can sildenafil treat primary premature ejaculation? A prospective clinical study. Int J Urol 14 (2007), 331–335.
23. McMahon, C.G., Stuckey, B.G., Andersen, M., et al. Efficacy of sildenafil citrate (Viagra) in men with premature ejaculation. J Sex Med 2 (2005), 368–375.
24. Zhang, X.S., Wang, Y.X., Huang, X.Y., et al. Comparison between sildenafil plus sertraline and sertraline alone in the treatment with premature ejaculation. Zhonghua Nan Ke Xue 11 (2005), 520–522 525.
25. Salonia, A., Maga, T., Colombo, R., et al. A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation. J Urol 168 (2002), 2486–2489.
26. Lue, T.F., Giuliano, F., Montorsi, F., et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 1 (2004), 6–23.
27. Waldinger, M.D., Lifelong premature ejaculation: from authority-based to evidence-based medicine. BJU Int 93 (2004), 201–207.
28. De Amicis, L.A., Goldberg, D.C., LoPiccolo, J., et al. Clinical follow-up of couples treated for sexual dysfunction. Arch Sex Behav 14 (1985), 467–489.
29. Anastasios, D., Asimakopoulos, M.D., Roberto Miano, M.D., et al. Does current scientific and clinical evidence support the use of phosphodiesterase type 5 inhibitors for the treatment of premature ejaculation? A systematic review and meta-analysis. J Sex Med 9 (2012), 2404–2416.
30. Althof, E., McMahon, G., Waldinger, D., et al. An update of the International Society of Sexual Medicine's Guidelines for the diagnosis and treatment of premature ejaculation (PE). Sex Med 2 (2014), 60–90.